|
1
|
Ostrom QT, Gittleman H, Liao P,
Vecchione-Koval T, Wolinsky Y, Kruchko C and Barnholtz-Sloan JS:
CBTRUS statistical report: Primary brain and other central nervous
system tumors diagnosed in the United States in 2010–2014. Neuro
Oncol. 19 (Suppl 5):v1–v88. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Weller M, van den Bent M, Preusser M, Le
Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven
L, et al: EANO guidelines on the diagnosis and treatment of diffuse
gliomas of adulthood. Nat Rev Clin Oncol. 18:170–186. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun X and Turcan S: From laboratory
studies to clinical trials: Temozolomide use in IDH-mutant gliomas.
Cells. 10:12252021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Patel KV, Ferrucci L, Ershler WB, Longo DL
and Guralnik JM: Red blood cell distribution width and the risk of
death in middle-aged and older adults. Arch Intern Med.
169:515–523. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lippi G, Targher G, Montagnana M, Salvagno
GL, Zoppini G and Guidi GC: Relation between red blood cell
distribution width and inflammatory biomarkers in a large cohort of
unselected outpatients. Arch Pathol Lab Med. 133:628–632. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Salvagno GL, Sanchis-Gomar F, Picanza A
and Lippi G: Red blood cell distribution width: A simple parameter
with multiple clinical applications. Crit Rev Clin Lab Sci.
52:86–105. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Aktimur R, Cetinkunar S, Yildirim K,
Aktimur SH, Ugurlucan M and Ozlem N: Neutrophil-to-lymphocyte ratio
as a diagnostic biomarker for the diagnosis of acute mesenteric
ischemia. Eur J Trauma Emerg Surg. 42:363–368. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hu L, Li M, Ding Y, Pu L, Liu J, Xie J,
Cabanero M, Li J, Xiang R and Xiong S: Prognostic value of RDW in
cancers: A systematic review and meta-analysis. Oncotarget.
8:16027–16035. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fu Y, Mao Y, Chen S, Yang A and Zhang Q: A
novel inflammation- and nutrition-based prognostic system for
patients with laryngeal squamous cell carcinoma: Combination of red
blood cell distribution width and body mass index (COR-BMI). PLoS
One. 11:e01632822016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kemal Y, Demirag G, Baş B, Önem S, Teker F
and Yücel İ: The value of red blood cell distribution width in
endometrial cancer. Clin Chem Lab Med. 53:823–827. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hirahara N, Matsubara T, Kawahara D,
Mizota Y, Ishibashi S and Tajima Y: Prognostic value of
hematological parameters in patients undergoing esophagectomy for
esophageal squamous cell carcinoma. Int J Clin Oncol. 21:909–919.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wen ZL, Zhou X and Xiao DC: Is red blood
cell distribution width a prognostic factor for colorectal cancer?
A meta-analysis. Front Surg. 9:9451262022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schneider M, Schäfer N, Apallas S,
Potthoff AL, Bode C, Güresir E, Heimann M, Lehmann F, Scharnböck E,
Schaub C, et al: Red blood cell distribution width to platelet
ratio substantiates preoperative survival prediction in patients
with newly-diagnosed glioblastoma. J Neurooncol. 154:229–235. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Auezova R, Ryskeldiev N, Doskaliyev A,
Kuanyshev Y, Zhetpisbaev B, Aldiyarova N, Ivanova N, Akshulakov S
and Auezova L: Association of preoperative levels of selected blood
inflammatory markers with prognosis in gliomas. Onco Targets Ther.
9:6111–6117. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liang RF, Li M, Yang Y, Mao Q and Liu YH:
Significance of pretreatment red blood cell distribution width in
patients with newly diagnosed glioblastoma. Med Sci Monit.
23:3217–3223. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bao Y, Yang M, Jin C, Hou S, Shi B, Shi J
and Lin N: Preoperative hematologic inflammatory markers as
prognostic factors in patients with glioma. World Neurosurg.
119:e710–e716. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu W, Wang D, Zheng X, Ou Q and Huang L:
Sex-dependent association of preoperative hematologic markers with
glioma grade and progression. J Neurooncol. 137:279–287. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Auezova R, Ivanova N, Akshulakov S,
Zhetpisbaev B, Kozhakhmetova A, Ryskeldiyev N, Mustafin K, Teltayev
D and Auezova L: Isocitrate dehydrogenase 1 mutation is associated
with reduced levels of inflammation in glioma patients. Cancer
Manag Res. 11:3227–3236. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kaisman-Elbaz T, Elbaz Y, Merkin V, Dym L,
Noy A, Atar-Vardi M, Bari R, Turiel S, Alt A, Zamed T, et al:
Hemoglobin levels and red blood cells distribution width highlights
glioblastoma patients subgroup with improved median overall
survival. Front Oncol. 10:4322020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yan OY, Teng HB, Fu SN, Chen YZ and Liu F:
Temporal muscle thickness is an independent prognostic biomarker in
patients with glioma: Analysis of 261 cases. Cancer Manag Res.
13:6621–6632. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Moher D, Liberati A, Tetzlaff J and Altman
DG; PRISMA Group, : Preferred reporting items for systematic
reviews and meta-analyses: The PRISMA statement. PLoS Med.
6:e10000972009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Stang A: Critical evaluation of the
Newcastle-Ottawa scale for the assessment of the quality of
nonrandomized studies in meta-analyses. Eur J Epidemiol.
25:603–605. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ioannidis JP: Interpretation of tests of
heterogeneity and bias in meta-analysis. J Eval Clin Pract.
14:951–957. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Higgins JP, Thompson SG, Deeks JJ and
Altman DG: Measuring inconsistency in meta-analyses. BMJ.
327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Higgins JPT, Thomas J, Chandler J,
Cumpston M, Li T, Page MJ and Welch VA: Cochrane Handbook for
Systematic Reviews of Interventions. 2nd edition. John Wiley &
Sons; Chichester: 2019, View Article : Google Scholar
|
|
27
|
Weller J, Tzaridis T, Mack F, Steinbach
JP, Schlegel U, Hau P, Krex D, Grauer O, Goldbrunner R, Bähr O, et
al: Health-related quality of life and neurocognitive functioning
with lomustine-temozolomide versus temozolomide in patients with
newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): A
randomised, multicentre, open-label, phase 3 trial. Lancet Oncol.
20:1444–1453. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Travers S and Litofsky NS: Daily lifestyle
modifications to improve quality of life and survival in
glioblastoma: A review. Brain Sci. 11:5332021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schuss P, Lehmann F, Schäfer N, Bode C,
Scharnböck E, Schaub C, Heimann M, Potthoff AL, Weller J, Güresir
E, et al: Postoperative prolonged mechanical ventilation in
patients with newly diagnosed glioblastoma-an unrecognized
prognostic factor. Front Oncol. 10:6075572020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schneider M, Potthoff AL, Scharnböck E,
Heimann M, Schäfer N, Weller J, Schaub C, Jacobs AH, Güresir E,
Herrlinger U, et al: Newly diagnosed glioblastoma in geriatric (65
+) patients: Impact of patients frailty, comorbidity burden and
obesity on overall survival. J Neurooncol. 149:421–427. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sacko A, Hou MM, Temgoua M, Alkhafaji A,
Marantidou A, Belin C, Mandonnet E, Ursu R, Doridam J, Coman I, et
al: Evolution of the Karnosky performance status throughout life in
glioblastoma patients. J Neurooncol. 122:567–573. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Förhécz Z, Gombos T, Borgulya G, Pozsonyi
Z, Prohászka Z and Jánoskuti L: Red cell distribution width in
heart failure: Prediction of clinical events and relationship with
markers of ineffective erythropoiesis, inflammation, renal
function, and nutritional state. Am Heart J. 158:659–666. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lappé JM, Horne BD, Shah SH, May HT,
Muhlestein JB, Lappé DL, Kfoury AG, Carlquist JF, Budge D,
Alharethi R, et al: Red cell distribution width, C-reactive
protein, the complete blood count, and mortality in patients with
coronary disease and a normal comparison population. Clin Chim
Acta. 412:2094–2099. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schneider M, Schäfer N, Bode C, Borger V,
Eichhorn L, Giordano FA, Güresir E, Heimann M, Ko YD, Lehmann F, et
al: Prognostic value of preoperative inflammatory markers in
melanoma patients with brain metastases. J Clin Med. 10:6342021.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang Y, Hu X, Xu W, Wang H, Huang Y and
Che G: Prognostic value of a novel scoring system using
inflammatory response biomarkers in non-small cell lung cancer: A
retrospective study. Thorac Cancer. 10:1402–1411. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hao Y, Li X, Chen H, Huo H, Liu Z, Tian F
and Chai E: A cumulative score based on preoperative
neutrophil-lymphocyte ratio and fibrinogen in predicting overall
survival of patients with glioblastoma multiforme. World Neurosurg.
128:e427–e433. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zheng SH, Huang JL, Chen M, Wang BL, Ou QS
and Huang SY: Diagnostic value of preoperative inflammatory markers
in patients with glioma: A multicenter cohort study. J Neurosurg.
129:583–592. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Morgillo F, Dallio M, Della Corte CM,
Gravina AG, Viscardi G, Loguercio C, Ciardiello F and Federico A:
Carcinogenesis as a result of multiple inflammatory and oxidative
hits: A comprehensive review from tumor microenvironment to gut
microbiota. Neoplasia. 20:721–733. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Elinav E, Nowarski R, Thaiss CA, Hu B, Jin
C and Flavell RA: Inflammation-induced cancer: Crosstalk between
tumours, immune cells and microorganisms. Nat Rev Cancer.
13:759–771. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Othman N, Jamal R and Abu N:
Cancer-derived exosomes as effectors of key inflammation-related
players. Front Immunol. 10:21032019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Azambuja JH, Ludwig N, Yerneni SS,
Braganhol E and Whiteside TL: Arginase-1+ exosomes from
reprogrammed macrophages promote glioblastoma progression. Int J
Mol Sci. 21:39902020. View Article : Google Scholar : PubMed/NCBI
|
